ライフサイエンスコーパス: interleukin-5

1 ment was likely due to systemic reduction in interleukin 5.

2 correlated with levels of tryptase, EDN, and interleukin-5.

3 asma eosinophil-derived neurotoxin (EDN) and interleukin-5.

4 roduced interferon-gamma and lower levels of interleukin-5.

5 ing mice with neutralizing antiserum against interleukin-5.

6 ryptase in sputum and lower plasma levels of interleukin-5.

7 ukin-2, interferon-gamma, interleukin-4, and interleukin-5.

8 umab, a monoclonal antibody directed against interleukin-5.

9 duction of granzyme B, interferon-gamma, and interleukin-5.

10 e the lack of production of the Th2 cytokine interleukin 5 and the chemokine eotaxin, which are cruci

11 ith airway eosinophils and concentrations of interleukin-5 and -13.

12 uch as increased expression of IgA-promoting interleukin-5 and anti-inflammatory transforming growth

13 This review highlights current literature on interleukin-5 and eosinophil production.

14 E, IgG, IgG1, and IgG2a levels as well as in interleukin-5 and interferon-gamma levels in BALF and in

15 terized by elevated antibody titers and high interleukin-5 and interleukin-10 cytokine levels; import

16 esize extremely low levels of interleukin-4, interleukin-5 and interleukin-10, but normal amounts of

17 n-gamma in the type-1 response, and enhanced interleukin-5 and interleukin-13 in the type-2 response.

18 ce of adaptive T-cell immunity that involves interleukin-5 and interleukin-13-induced esophageal epit

19 pment of eosinophilic esophagitis, including interleukin-5 and interleukin-13.

20 s, such as humanised antibodies against IgE, interleukin 5, and interleukin 13, offer hope to improve

21 molecular signaling, physiologic sources of interleukin-5, and interactions between interleukin-5, e

22 Mig, as well as variable induction of B7.1, interleukin-5, and interferon gamma expression was noted

23 vealed induction of IP-10, Mig, B7.1 (CD80), interleukin-5, and interferon gamma in selected patients

24 and in vivo, with more robust interleukin-4, interleukin-5, and interleukin-13 production than their

25 , RSV F(51-66)-specific CD4 T cells secreted interleukin-5, and mice developed pulmonary eosinophilia

26 ntiation and gene expression, independent of interleukin-5, and regardless of inclusion of cytokines

27 -D content, gamma interferon, interleukin-4, interleukin-5, and tumor necrosis factor alpha in BAL fl

28 rferon-gamma-producing) and type 2 T helper (interleukin-5- and -10-producing) peripheral blood lymph

29 ron-gamma, and interleukin-6, with increased interleukin-5] and decreased CNS white matter inflammati

30 ies examining cytokine blockers such as anti-interleukin-5, anti-interleukin-4Ralpha, and anti-interl

31 ministration's recommendation to use an anti-interleukin-5 antibody for the treatment of severe eosin

32 yte-macrophage colony-stimulating factor and interleukin 5, Bax spontaneously underwent activation an

33 tion of interferon-gamma, interleukin-2, and interleukin-5, but up-regulates transforming growth fact

34 patient who did not respond had raised serum interleukin-5 concentrations.

35 s with hypereosinophilic syndrome and normal interleukin-5 concentrations.

36 interferon-gamma) and Th2 (interleukin-4 and interleukin-5) cytokines.

37 of fibroblasts in soft agar and relieves the interleukin-5 dependence of a pre-B-cell line.

38 hybridization analysis, mT4 is expressed in interleukin-5-dependent mouse eosinophils, as well as in

39 ked down-regulation of the hSP-C promoter is interleukin-5-dependent, implying a critical role for eo

40 s of interleukin-5, and interactions between interleukin-5, eosinophils, and the bone marrow microenv

41 This mRNA was expressed at high levels in interleukin 5-exposed eosinophils, elicited peritoneal m

42 ated the infection depending on the level of interleukin-5 expression.

43 show that transcriptional repression of the Interleukin-5 gene involves recruitment of GR to a DNA r

44 cal keratitis in control C57Bl/6 mice and in interleukin-5 gene knockout (IL-5(-/-)) mice.

45 orm infection, albendazole treatment reduced interleukin-5 (geometric mean ratio 0.50, 95% CI 0.30-0.

46 Interleukin-5 has been identified as a major regulator o

47 persistent airway eosinophilia, blockade of interleukin-5 has significant steroid-sparing effects an

48 lonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbat

49 ntibodies targeted to interleukin 4alpha and interleukin 5 have shown substantial benefit in patients

50 The high-affinity receptor for human interleukin-5 (hIL-5) is composed of alpha and beta subu

51 with monoclonal antibodies directed against interleukin-5, IgE or CD4 yielded results that were crit

52 inophil survival-promoting cytokines such as interleukin 5 (IL-5) and granulocyte-macrophage colony-s

53 cells (Th2 cells) are the primary source of interleukin 5 (IL-5) and IL-13 during type 2 (allergic)

54 In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vacci

55 y suggests a potentially protective role for interleukin 5 (IL-5) in sepsis; however, the loss of eos

56 Culture of eosinophils with interleukin 5 (IL-5) leads to a two- to fourfold increas

57 The ligand-binding alpha-chain of the human interleukin 5 (IL-5) receptor was expressed in its solub

58 Peripheral blood mononuclear cell interleukin 5 (IL-5) responses to F-OvAg and Smf decline

59 of single-chain and monomeric forms of human interleukin 5 (IL-5) was performed to investigate mechan

60 The normally dimeric human interleukin 5 (IL-5) was re-engineered into two monomeri

61 n and immunoglobulin production by secreting interleukin 5 (IL-5).

62 ated by the central eosinophil growth factor interleukin 5 (IL-5).

63 d mRNA expression of the TH2-type cytokines, interleukin-5 (IL-5) and granulocyte-macrophage colony-s

64 s (n = 33) had higher levels of constitutive interleukin-5 (IL-5) and IL-10, increased microfilarial

65 2 ILCs (ILC2s) produce type 2 cytokines like interleukin-5 (IL-5) and IL-13 and require GATA3, and gr

66 xpression of mRNA for the Th2-type cytokines interleukin-5 (IL-5) and IL-13 as well as some increase

67 g epithelial cells inducing the elevation of interleukin-5 (IL-5) and IL-13 from natural helper (NH)

68 increased amounts of inflammatory cytokines interleukin-5 (IL-5) and IL-13 in lung lavage fluid, dec

69 leads to an increase in the Type 2 cytokines interleukin-5 (IL-5) and IL-13; however, the effect of s

70 s of PP CD4(+) T helper (Th) cells secreting interleukin-5 (IL-5) and IL-6 and splenic CD4(+) Th cell

71 Surprisingly, GALT DCs, together with interleukin-5 (IL-5) and IL-6, also provided a milieu fo

72 ml), and culture supernates were assayed for interleukin-5 (IL-5) and interferon-gamma by enzyme-link

73 in the bronchoalveolar lavage fluid (BALF); interleukin-5 (IL-5) and leukotriene concentrations in B

74 ent killer cell activity, elevated levels of interleukin-5 (IL-5) and percentages of eosinophils in t

75 Plasma interleukin-5 (IL-5) and RANTES levels peaked 1 to 2 day

76 Observations that monoclonal antibodies to interleukin-5 (IL-5) are well tolerated appear unsurpris

77 We also identify interleukin-5 (IL-5) as a novel inducer of killer B cell

78 We show that interleukin-5 (IL-5) deficiency profoundly impairs VAT e

79 Interleukin-5 (IL-5) drives the terminal differentiation

80 To investigate the role of interleukin-5 (IL-5) during Toxoplasma gondii infection,

81 Gamma interferon (IFN-gamma) and interleukin-5 (IL-5) enzyme-linked immunospot (ELISPOT)

82 n of the airways and increased production of interleukin-5 (IL-5) in cultures of peribronchial lymph

83 Our studies examined the role of interleukin-5 (IL-5) in helminth-induced pulmonary eosin

84 P-D have reduced eosinophil infiltration and interleukin-5 (IL-5) in lung lavage fluid.

85 hil-active cytokines showed unique patterns: interleukin-5 (IL-5) increased in the antigen segment on

86 Interleukin-5 (IL-5) is a hematopoietic differentiation

87 ition of eosinophil apoptosis by exposure to interleukin-5 (IL-5) is associated with the development

88 Interleukin-5 (IL-5) is essential for the formation of e

89 Here, we used interleukin-5 (IL-5) knockout (KO) mice to determine whe

90 Response was not predicted by serum interleukin-5 (IL-5) levels or presence of the FIP1L1/PD

91 netic interactions of a humanized anti-human interleukin-5 (IL-5) monoclonal antibody (SCH 55700) wit

92 p of patients with HES show T-cell-dependent interleukin-5 (IL-5) overexpression, we determined if ex

93 Interleukin-5 (IL-5) plays a central role in the differe

94 Preliminary data showing enhanced interleukin-5 (IL-5) production by T cells from infected

95 primed T cells and CD4+ T cells to increase interleukin-5 (IL-5) production.

96 Interleukin-5 (IL-5) regulates the growth and function o

97 Interleukin-5 (IL-5) specifically induces the differenti

98 transcript levels rapidly increase following interleukin-5 (IL-5) stimulation of CD34(+) hematopoieti

99 of phagocytizing bacteria, neutralization of interleukin-5 (IL-5) to inhibit eosinophil recruitment l

100 4(+) gamma interferon (IFN-gamma)(+), CD4(+) interleukin-5 (IL-5)(+), and CD4(+) IL-17A(+) phenotypes

101 (GM-CSF) and the single structural domain of interleukin-5 (IL-5), all of which share a common recept

102 suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation,

103 nts using a humanised monoclonal antibody to interleukin-5 (IL-5), and animal studies involving speci

104 of CII-specific interferon-gamma (IFNgamma), interleukin-5 (IL-5), and IL-10 was determined by enzyme

105 nhibited the production of gamma interferon, interleukin-5 (IL-5), and IL-12.

106 interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), and tumor necrosis factor alpha (T

107 ession of three eosinophil chemoattractants: interleukin-5 (IL-5), eotaxin, and regulated on activato

108 Antigen-specific interleukin-5 (IL-5), gamma interferon (IFN-gamma), and

109 However, elevated levels of interleukin-5 (IL-5), generated by transgenic or pharmac

110 increased levels of eosinophils, mast cells, interleukin-5 (IL-5), IL-13, gamma interferon, immunoglo

111 The eosinophil-active cytokines interleukin-5 (IL-5), IL-6, and IL-10 were strikingly el

112 at regions of LSA-1 stimulated production of interleukin-5 (IL-5), interleukin-10 (IL-10), gamma inte

113 To delineate a role for interleukin-5 (IL-5), interleukin-4 (IL-4), and interfer

114 reatment with the rat anti-mouse antibody to interleukin-5 (IL-5), TRFK-5 (10-300 microg, intraperito

115 Interleukin-5 (IL-5), which is produced by CD4(+) T help

116 During schistosomiasis, interleukin-5 (IL-5)-dependent eosinophil responses have

117 levels of malaria-specific IgG1 antibody and interleukin-5 (IL-5)-producing T cells.

118 s, we analyzed eosinophil differentiation in interleukin-5 (IL-5)-stimulated umbilical cord stem cell

119 is, and activation is primarily regulated by interleukin-5 (IL-5).

120 onstrated with parathyroid hormone (PTH) and interleukin-5 (IL-5).

121 t of T cells in the airway and generation of interleukin-5 (IL-5).

122 gamma [IFN-gamma]) as well as selective Th2 (interleukin-5 [IL-5] and IL-6) cytokine responses than d

123 in T cell cytokine levels (interferon-gamma, interleukin-5 [IL-5], IL-10, IL-17) were detected after

124 s, interleukin 3 (Il3), interleukin 4 (Il4), interleukin 5 (Il5), interleukin 13 (Il13), and granuloc

125 ial for high affinity interaction with human interleukin 5 (IL5).

126 previously demonstrated that AF17121 mimics Interleukin-5 (IL5) by binding in a region of IL5Ralpha

127 21 is a library-derived antagonist for human interleukin-5 (IL5) receptor alpha (IL5Ralpha) and inhib

128 sinophils around the airway, lower levels of interleukin 5 in the lung, and reduced serum levels of i

129 ponses were associated with the detection of interleukin 5 in the serum.

130 This was characterized by increased interleukin-5 in lung supernatants and an increase in G-

131 and -13 in antigen-induced dysmotility, and interleukin-5 in the pathogenesis of mucosal eosinophili

132 st clones secreted gamma interferon, but not interleukin-5, in response to antigen.

133 nregulation of Th2 cytokines (interleukin 4, interleukin 5, interleukin 10, interleukin 13).

134 ll responsive (as measured by proliferation, interleukin-5, interleukin-10, interferon-gamma, and gra

135 ecreased leukocytes and mediators, including interleukin-5, interleukin-13, eotaxin, prostanoids and

136 This analysis indicated that interleukin-5, interleukin-6, and granulocyte-colony sti

137 ssayed for interleukin-1beta, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin

138 rleukin-1beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-9, interleukin

139 interleukin-2 receptor-alpha, interleukin-4, interleukin-5, interleukin-7, interleukin-13, interleuki

140 Interleukin-5 is a Th2 homodimeric cytokine involved in

141 th mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exace

142 Serum interleukin 5 levels and eosinophil activation, as asses

143 a significant reduction in interleukin-4 and interleukin-5 levels and a significant increase in inter

144 vels (P<.06) and a tendency toward increased interleukin-5 levels, compared with helminth-free patien

145 all 4 responding patients had elevated serum interleukin-5 levels.

146 ng of the interleukin 5 receptor rather than interleukin 5 ligand.

147 controls, levels of the chemotactic factors interleukin-5, macrophage inflammatory protein-1 alpha,

148 ilic syndrome, the therapeutic niche of anti-interleukin-5 (mepolizumab) and anti-CD52 (alemtuzumab)

149 Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinoph

150 In this study, we report that anti-interleukin-5 monoclonal antibody (TRFK-5) treatment can

151 Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on the

152 These results demonstrate that anti-interleukin-5 monoclonal antibody treatment can effectiv

153 valuating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patie

154 Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinop

155 tle phenotypes, whereas other genes, such as interleukin-5 or osteoprotegerin, were initially identif

156 actor beta, gamma interferon, interleukin-4, interleukin-5, or interleukin-6 for all mouse strains.

157 Interleukin-5 plays a pivotal role in the regulation of

158 are the major source of interferon-gamma and interleukin-5 produced in response to alloantigen.

159 n-atopic donors suppressed proliferation and interleukin 5 production by their own allergen-stimulate

160 HPV antigen--specific interferon--gamma and interleukin-5 production were measured from PBMC culture

161 ffect on interferon-gamma production than on interleukin-5 production.

162 phils stimulated with IgA immune complex and interleukin 5 promote neurite extension of the PC-12 phe

163 ty also showed significant correlations with interleukin-5 (r = 0.66, p = 0.002), transforming growth

164 in patients who died, with a serum G-CSF to interleukin 5 ratio of >100 at admission being the most

165 Human interleukin 5 receptor alpha (IL5Ralpha) comprises three

166 efficacy and safety of benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody that de

167 Benralizumab is a humanised, anti-interleukin 5 receptor alpha monoclonal antibody that di

168 ls per muL, possibly due to targeting of the interleukin 5 receptor rather than interleukin 5 ligand.

169 BCR) or the mast cell Fcepsilon receptor, or interleukin 5 receptor stimulation each induced rapid ph

170 contrast, introduction and activation of the interleukin-5 receptor (IL-5R) or of the granulocyte-mac

171 lular domain of the alpha chain of the human interleukin-5 receptor (IL-5Ralpha), but share no primar

172 E) is a library-derived antagonist for human Interleukin-5 receptor alpha (IL5Ralpha).

173 ically important gene products (for example, interleukin-5 receptor alpha chain, IL-5R alpha).

174 phage surface and binding of scIL-5 phage to interleukin-5 receptor alpha chain.

175 Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor alpha monoclonal antibody that ha

176 ralizumab is a humanised, afucosylated, anti-interleukin-5 receptor alpha monoclonal antibody that in

177 Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, deplet

178 benralizumab, a monoclonal antibody against interleukin-5 receptor alpha that depletes eosinophils b

179 affinity changes mediated by IgE receptor or interleukin-5 receptor persist longer.

180 dy directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the in

181 Expression of the interleukin-5 receptor-alpha (IL-5Ralpha) chain is thoug

182 utive and alternative splicing of the murine interleukin-5 receptor-alpha (IL-5Ralpha) chain pre-mRNA

183 n (betac), shared with the interleukin-3 and interleukin-5 receptors.

184 production are enhanced by interleukin-4 and interleukin-5, respectively, these findings suggest that

185 nduction of PA-specific gamma interferon and interleukin 5 responses was observed in splenocytes.

186 Interleukin-5 responses were not different among CD, UC,

187 1 type (ie, strong interferon-gamma and weak interleukin-5 responses).

188 eatment with TRFK5, a monoclonal antibody to interleukin-5, resulted in a 76% decrease in eosinophil

189 n the presence of 10 pg/ml human recombinant interleukin-5 (rhIL-5) and activated with formyl-met-leu

190 nctional phage display of single chain human interleukin-5 (scIL-5) and its use for receptor-binding

191 Dual asymmetric mutagenesis of single-chain interleukin 5 (scIL5) was used to obtain evidence that t

192 Although their Her-2-specific IgG1 and interleukin-5-secreting T cells increased, the levels of

193 Immunization with antigen and AlOH induced interleukin-5-secreting, antigen-specific T cells, and i

194 ody (mAb) inhibited eosinophil infiltration, interleukin 5 secretion, and IgE production.

195 daily; four male patients with normal serum interleukin 5 showed complete haematological responses;

196 ee genes, interleukin-4, interleukin-13, and interleukin-5, spread over 120 kilobases.

197 e sequencing of a cDNA library prepared from interleukin-5-stimulated umbilical cord precursor cells

198 te-macrophage colony-stimulating factor, and interleukin-5, suggesting a role for the beta common (be

199 en-specific gamma interferon (IFN-gamma) and interleukin 5 to levels comparable to those achieved wit

200 We hypothesized that J558L HI, an interleukin 5-transfected murine plasmacytoma that is in

201 Moreover, larvae were killed in naive interleukin-5 transgenic mice, and the killing coincided

202 In vivo, interleukin-5 transgenic mice, which have profound eosin

203 evented by anti-very late antigen-4 and anti-interleukin-5 treatments, which blocked airway eosinophi

204 The cytokine interleukin-5 was chemokinetic for bone marrow eosinophi

205 analysis with gene-targeted mice showed that interleukin-5 was required for esophageal eosinophilia a

206 ere not degranulated and increased levels of interleukin-5 were measured in bronchoalveolar lavage an

207 locyte colony-stimulating factor, as well as interleukin 5, which may be responsible for the decrease

208 mab, a humanized monoclonal antibody against interleukin-5, which was administered as either a 75-mg

209 strains of mice produced only low levels of interleukin-5, with no detectable level of interleukin-4

210 ux and shifted cytokine production away from interleukin-5 without reducing the resistance to viral r

211 Wild type human (h) interleukin 5 (wt IL5) is composed of two identical pept